Skip to main content
Premium Trial:

Request an Annual Quote

BioGx Lands CE Mark for Influenza, RSV Assay

NEW YORK (GenomeWeb) – BioGx announced it has received CE-IVD marking for a real-time PCR-based test to detect Influenza A, Influenza B, and respiratory syncytial virus.

The assay uses samples from nasopharyngeal swabs and runs on the Becton Dickinson BD Max system. Offered as a single tube that snaps into the BD Max RNA/DNA extraction cartridge, the test increases lab efficiency, the firm said in a statement.

While BioGx is based in Birmingham, Alabama, the test is not currently available for sale in the US. Additional snap-in tests in the company's Sample-Ready product line will also be available soon, BioGx CEO Shazi Iqbal said in a statement.

This is the latest influenza and RSV assay to get a CE Mark since Luminex's Aries Flu A/B & RSV assay did in July.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.